Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Provan, Sella Aarrestad
Hammer, Hilde Berner
Di Giuseppe, Daniela
Hetland, Merete Lund
MetadataShow full item record
CitationDelcoigne B, Provan SA, Hammer HB, et al. Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration [published online ahead of print, 2022 Feb 9]. Rheumatology (Oxford). 2022;keac081. doi:10.1093/rheumatology/keac081
AbstractObjectives: To investigate whether patient-reported outcomes vary across countries and are influenced by cultural/contextual factors. Specifically, we aimed to assess inter-country differences in tender joint count (TJC), pain and patient's global health assessment (PGA), and their impact on disease activity (DAS28-CRP) in rheumatoid arthritis (RA) patients from five Nordic countries. Methods: We collected data (baseline, 3- and 12-months) from rheumatology registers in the five countries comprising RA patients starting a first-ever methotrexate or a first-ever tumor necrosis factor inhibitor (TNFi). In order to assess the role of context (=country), we separately modelled TJC, pain and PGA as functions of objective variables (C-reactive protein, swollen joint count, age, sex, calendar period and disease duration) with linear models. Analyses were performed at each time point and for both treatments. We further assessed the impact of inter-country differences on DAS28-CRP. Results: 27 645 RA patients started methotrexate and 19 733 started a TNFi. Crude inter-country differences at methotrexate start amounted to up to 4 points (28 points scale) for TJC, 10 and 27 points (0-100 scale) for pain and PGA, respectively. Corresponding numbers at TNFi start were 3 (TJC), 27 (pain) and 24 (PGA) points. All differences were reduced at 3- and 12-months, and attenuated when adjusting for the objective variables. The variation in predicted DAS28-CRP across countries amounted to < 0.5 units. Conclusions: Inter-country differences in TJC, pain and PGA are greater than expected based on differences in objective measures, but have a small clinical impact on DAS28-CRP across countries. Keywords: Patient-reported outcome (PRO); disease activity; inter-country comparison; pain; rheumatoid arthritis.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
Rights© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: firstname.lastname@example.org.
- Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
- Authors: El Miedany Y, Youssef SS, El Gaafary M
- Issue date: 2006 Mar
- Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
- Authors: Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS
- Issue date: 2020 Apr
- Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
- Authors: Choy T, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, Keystone EC, Pope JE, CATCH Investigators.
- Issue date: 2014 Mar
- Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
- Authors: Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A
- Issue date: 2011 Aug
- Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
- Authors: Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G
- Issue date: 2014 Oct